Calnexin Inhibition Alleviates Arthritis Symptoms
Albatroz Therapeutics announced research published in •Nature Communications• demonstrating a novel therapeutic approach for arthritis using anti-Calnexin antibodies. The...
Clearmind Medicine Initiates U.S. Clinical Trial for Alcohol Use Disorder
Clearmind Medicine Inc. has launched a Phase I/IIa clinical trial for its novel Alcohol Use Disorder (AUD) treatment, CMND-100,...
Riva Biologics Presents Positive Syn-004 Data in Allo-HCT
Theriva Biologics announced the presentation of interim safety and pharmacokinetic data from its ongoing Phase 1b/2a clinical trial of...
New Patient Data Shows Promise for Oxylanthanum Carbonate in Hyperphosphatemia
Unicycive Therapeutics announced positive patient-reported outcomes from a Phase 2 trial of its oxylanthanum carbonate (OLC) drug for hyperphosphatemia...
Briapro Develops Novel B7-H3 Antibodies
BriaPro Therapeutics, a majority-owned subsidiary of BriaCell Therapeutics, is developing novel, high-affinity antibodies targeting B7-H3, a molecule implicated in...
Liberty® Robotic System Achieves 100% Navigation Success in Trial
Microbot Medical presented positive data from its ACCESS-PVI pivotal trial for the LIBERTY® Endovascular Robotic System at the Society...
Grace Therapeutics and FDA Align on GTX-104 NDA Submission
Grace Therapeutics, a late-stage biopharmaceutical company, announced positive feedback from the FDA regarding its planned New Drug Application (NDA)...
Context Therapeutics Doses First Patient in Phase 1 Trial of CT-95
Context Therapeutics has dosed the first patient in a Phase 1 clinical trial for CT-95, a bispecific antibody targeting...
Bemnifosbuvir and Ruzasvir in Phase 3 HCV Study
Atea Pharmaceuticals has initiated its Phase 3 C-BEYOND trial, evaluating the bemnifosbuvir and ruzasvir regimen for chronic hepatitis C...
KSQ Doses First Patient in CRISPR TIL Therapy Trial
KSQ Therapeutics has dosed the first patient in a Phase 1/2 clinical trial for KSQ-004EX, a CRISPR-engineered tumor-infiltrating lymphocyte...